Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2641-2649

  Hollingshead, Holly E ^a   Killins, Renee L ^a   Borland, Michael G ^a   Girroir, Elizabeth E ^a   Billin, Andrew N ^b   Willson, Timothy M ^b   Sharma, Arun K ^c   Amin, Shantu ^c   Gonzalez, Frank J ^d   Peters, Jeffrey M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PENN STATE CANCER INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CYCLOOXYGENASE 2; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PROTEIN KINASE B; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CATABOLISM; CELL PROLIFERATION; CELL STRAIN HCT116; CELL STRAIN HEPG2; CELL STRAIN HT29; COLON POLYP; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; FATTY ACID METABOLISM; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; INSULIN SENSITIVITY; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; SKELETAL MUSCLE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLONIC POLYPS; CULTURE MEDIA, SERUM-FREE; CYCLOOXYGENASE 2; HUMANS; LIGANDS; LIVER; MICE; MICE, INBRED C57BL; PHOSPHORYLATION; PPAR DELTA; PPAR-BETA; PROTO-ONCOGENE PROTEINS C-AKT; THIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36949036752     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm183     Document Type: Article

References (54)

1. Leibowitz,M.D. et al. (2000) Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett., 473, 333-336.
2. Oliver,W.R.Jr. et al. (2001) A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA, 98, 5306-5311.
3. Sprecher,D.L. et al. (2007) Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor {delta} agonist. Arterioscler. Thromb. Vasc. Biol., 27, 359-365.
4. van der Veen,J.N. et al. (2005) Reduced cholesterol absorption upon PPAR-delta activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res., 46, 526-534.
5. Wallace,J.M. et al. (2005) Effects of peroxisome proliferator-activated receptor {alpha}/{delta} agonists on HDL-cholesterol in vervet monkeys. J. Lipid Res., 46, 1009-1016.
6. Pelton,P. (2006) GW-501516 GlaxoSmithKline/ligand. Curr Opin. Investig. Drugs, 7, 360-370.
7. Barish,G.D. et al. (2006) PPAR delta: A dagger in the heart of the metabolic syndrome. J. Clin. Invest., 116, 590-597.
8. Gupta,R.A. et al. (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat. Med., 10, 245-247.
9. Wang,D. et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell, 6, 285-295.
10. Stephen,R.L. et al. (2004) Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res., 64 3162-3170.
11. Xu,L. et al. (2006) Cross-talk between peroxisome proliferator-activated receptor {delta}and cytosolic phospholipase A2 {alpha}/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells. Cancer Res., 66, 11859-11868.
12. Glinghammar,B. et al. (2003) PPARdelta activation induces COX-2 gene expressíon and cell proliferation in human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun., 308, 361-368.
13. Xu,L. et al. (2006) A novel positive feedback loop between PPARdelta and PGE2 signaling pathways for human cholangiocarcinoma cell growth. J. Biol. Chem., 281, 33982-33996.
14. Wang,D. et al. (2006) Crosstalk between peroxisome proliferator-activated receptor {delta} and VEGF stimulates cancer progression. Proc. Natl Acad. Sci. USA, 103, 19069-19074.
15. Shimada,T. et al. (2002) Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut, 50, 659-664.
16. Ding,G. et al. (2006) PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J. Mol. Cell. Cardiol., 40, 821-828.
17. Graham,T.L. et al. (2005) The PPAR[delta] agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis, 181, 29-37.
18. Jakobsen,M.A. et al. (2006) Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands. Scand. J. Immunol., 63, 330-337.
19. Kim,D.J. et al. (2006) PPARb/d selectively induces differentiation and inhibits cell proliferation. Cell Death Differ., 13, 53-60.
20. Nagasawa,T. et al. (2006) Effects of bezafibrate, PPAR pan-agonist and GW501516, PPARdelta agonist, on development of steatohepatitis in míce fed a methionine- and choline-deficient diet. Eur. J. Pharmacol., 536, 182-191.
21. Rival,Y. et al. (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol., 435 143-151.
22. Schmuth,M. et al. (2004) Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol., 122, 971-983.
23. Welch,J.S. et al. (2003) PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc. Natl Acad Sci. USA, 100, 6712-6717.
24. Woo,C.H. et al. (2006) ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. J. Biol. Chem., 281, 32164-32174.
25. Hollingshead,H.E. et al. (2007) PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig. Dis. Sci. doi: 10.1007/sl0620-006-9644-9.
26. Aung,C.S. et al. (2006) Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation. Biochem. Biophys. Res. Commun., 340, 656-660.
27. Burdick,A.D. et al. (2007) Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal., 19, 1163-1171.
28. Marin,H.E. et al. (2006) Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res., 66, 4394-4401.
29. Nadra,K. et al. (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol. Cell. Biol., 26, 3266-3281.
30. Tan,N.S. et al. (2001) Critical roles of PPARbeta/delta keratinocyte response to inflammation. Genes Dev., 15, 3263-3277.
31. Varnat,F. et al. (2006) PPARbeta/delta regulates paneth cell differentiation via controlling the hedgehog signaling pathway. Gastroenterology, 131, 538-553.
32. Westergaard,M. et al. (2001) Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands tetradecylthioacetic acid. J. Invest. Dermatol., 116, 702-712.
33. Ali,F.Y. et al. (2005) Role of prostacyclin receptor versus PPAR{beta} with treprostinil sodium on lung fibroblast proliferation. Am. J. Respir Cell. Mol. Biol., 34, 242-246.
34. Fukumoto,K. et al. (2005) Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth. FEBS Lett., 579, 3829-3836.
35. Kim,D.J. et al. (2004) Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem., 279, 23719-23727.
36. Kim,D.J. et al. (2005) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-rrgulation of kinase activity. J. Biol. Chem., 280, 9519-9527.
37. Martinasso,G. et al. (2006) EfFects of di(2-ethylhexyl) phthalate, a widely used peroxisome proliferator and plasticizer, on cell growth in the human keratinocyte cell line NCTC 2544. J. Toxicol. Environ. Health A, 69, 353-365.
38. Matthiessen,M.W. et al. (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand. J. Gastroenterol., 40, 198-205.
39. Peters,J.M. et al. (2000) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol., 20 5119-5128.
40. Planavila,A. et al. (2005) Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc. Res., 65, 832-841.
41. Ou,Y.C. et al. (2007) Indomethacin induces apoptosis in 786-0 renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur. J. Pharmacol., 563, 49-60.
42. Debard,C. et al. (2006) Short-term activation of peroxysome proliferator-activated receptor beta/delta increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients. J. Mol. Med., 84, 747-752.
43. Kramer,D.K. et al. (2005) Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Diabetes, 54, 1157-1163.
44. Kino,T. et al. (2007) The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition. Eur. J. Clin. Invest., 37, 425-433.
45. Berger,J. et al. (1999) Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J. Biol. Chem., 274, 6718-6725.
46. Sznaidman,M.L. et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg. Med. Chem. Lett., 13, 1517-1521.
47. Burdick,A.D. et al. (2006) The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal., 18, 9-20.
48. Wei,Z.L. et al. (2003) A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. J. Org. Chem., 68, 9116-9118.
49. Lee,C.H. et al. (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl Acad. Sci. USA, 103, 3444-3449.
50. Chawla,A. et al. (2003) PPAR{delta} is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. USA, 100, 1268-1273.
51. Tanaka,T. et al. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. USA, 100, 15924-15929.
52. Conway,J.G. et al. (1989) Relationship of oxidative damage to the hepato-carcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. Carcinogenesis, 10, 513-519.
53. Piqueras,L. et al. (2007) Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol., 27, 63-69.
54. Wang,D. et al. (2007) Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle, 6, 682-685.